Multiple Biologics for Multiple T2 Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by Indication.

"Disclosure A.B. received payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events from AstraZeneca, GSK, Sanofi, Chiesi, Regeneron, ABScience, Novartis, and was principal investigator in clinical trials for AstraZenaca, GSK and Boehringer Ingelheim. J.C. received payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events from AstraZeneca, GSK, Sanofi, Chiesi. V.D. received payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing or educational events from ABBVIE, Janssen, Lilly, Novartis and Sanofi. R.J. reports personal fees from IQVIA, during the conduct of the study; personal fees from Sanofi, outside the submitted work. M.M is affiliated with IQVIA. The authors report no other conflicts of interest in this work."